Previous 10 | Next 10 |
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $12.36. This new low was reached on approximately average trading volume as 843,000 shares traded hands, while the average 30-day volume is approximately 899,000 shares. Black Diamond Therapeutics Inc is a...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Shares of Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded today at $12.65, breaking its 52-week low. Approximately 843,000 shares have changed hands today, as compared to an average 30-day volume of 871,000 shares. In the past 52 weeks, shares of Black Diamond Therapeutics Inc. have...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $13.00. So far today approximately 843,000 shares have been exchanged, as compared to an average 30-day volume of 793,000 shares. Based on a current price of $13.09, Black Diamond Therapeutics Inc. is curr...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major stock market averages closed mixed for the week following a choppy day of trading Friday. The week saw the stock market bounced aro...
Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...
Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...
Black Diamond Therapeutics (BDTX) shares have tumbled nearly 30% in premarket trading after the company posted early-stage results of BDTX-189 in treating certain patients with advanced solid tumors.The dose-escalation portion enrolled patients with a broad range of tumor types...
Black Diamond Therapeutics (BDTX) -27% after presents Phase 1 Pharmacokinetic, safety, and preliminary efficacy data of BDTX-189 in advanced solid tumors harboring EGFR or HER2 alterationsKE Holdings (BEKE) -9% on Q1 earnings releaseMoSys (MOSY) -8%.Kohl's (KSS) -6%...
Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions Generally well-tolerated with medically manageable toxicities observed; safety profile compares favorably in the context of other agents in the c...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...